Zymeworks (ZYME) Analyst Targets Point to +36% Upside

Key Takeaways

• The central $42 target is the arithmetic mean of 14 current analyst price targets, rounded from a calculated mean of roughly $41.60.
• At a recent price near $30.80, reaching $42 implies about 36% upside—a substantial move rather than a marginal one.
• Individual targets range widely, from a low of $32 to a high of $58, reflecting genuine disagreement about how much of the pipeline is already priced in.
• Supporting factors include 2026 revenue guidance of $278–$292 million, the Theravance Biopharma acquisition, a strengthened balance sheet, and a near-unanimous Buy/Outperform analyst consensus.
• The largest risks are a rich trailing valuation, persistent net losses, clinical and regulatory execution, and short interest near 8% of the share count.
• For more detail, explore the Major News, Today's Price Move, Forecast, and Earnings pages for ZYME.
• Readers can also explore Trending AI Robots for AI-driven trading ideas across the market.

Analyst Price Targets and Consensus View

Zymeworks Inc. (ZYME) is a clinical-stage biopharmaceutical company, not an exchange-traded fund, so this analysis centers on sell-side price targets. Fourteen current targets were reviewed, spanning a low of $32 to a high of $58. The arithmetic mean is about $41.60, rounded to a $42 central target. Averages of 14 targets sit between roughly $40.70 and $41.70 across data providers, so $42 fairly represents the collected estimates without being mistaken for a single official consensus.

Sentiment is strikingly one-sided: the available ratings are effectively all Buy, Outperform, or Overweight, with no Hold or Sell ratings in the current set. Yet the wide range shows that agreement on direction does not equal agreement on magnitude. More cautious targets sit in the low-to-mid $30s—J.P. Morgan at $33, Truist and TD Cowen at $34—while H.C. Wainwright ($55), Jefferies ($52), and Leerink Partners ($58) anchor the bullish end. Recent activity has been a steady run of increases: Truist raised its target to $34, Citi to $39, B. Riley to $44, and H.C. Wainwright to $55, among others. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

ZYME shares recently traded near $30.80, giving the stock a market capitalization of roughly $2.1 billion. A move to $42 would require about 36% appreciation—properly described as a substantial gain. The shares have already delivered outsized returns, up nearly 87% over the trailing 52 weeks and recently trading within reach of the 52-week high of $31.49.

The path toward the target likely hinges on execution rather than re-rating alone. Zymeworks' lead asset, the HER2-targeting bispecific antibody zanidatamab (marketed through its partner as Ziihera for HER2-positive biliary tract cancer), anchors the pipeline, while the Theravance Biopharma acquisition adds respiratory products and near-term revenue. Management has guided to 2026 revenue of $278 million to $292 million, a sharp step-up from trailing revenue near $37 million, reflecting the acquired portfolio. Delivering on that guide and advancing earlier-stage programs would be the core mechanism for the shares to justify a higher valuation.

What Could Support a Move Toward the Target

• Stepped-up revenue guidance of $278–$292 million for 2026 following the Theravance acquisition.
• A near-unanimous analyst consensus with repeated, recent target increases rather than cuts.
• A stronger balance sheet: roughly $270 million in cash versus about $16 million in debt, aided by a $250 million Royalty Pharma financing.
• A $125 million share-buyback program, signaling management confidence in valuation.
• Continued clinical and regulatory progress for zanidatamab and the broader multifunctional-biotherapeutics pipeline.

What Could Prevent the Target From Being Reached

• Persistent losses—trailing net loss near $150 million—and a trailing price-to-sales ratio well above the broader biotech group, leaving little room for execution missteps.
• Clinical or regulatory setbacks for zanidatamab or earlier-stage assets.
• Integration and commercialization risks tied to the Theravance acquisition.
• Short interest near 8% of shares outstanding, which can amplify downside volatility.
• A wide target range ($32–$58) indicating that some analysts see far more limited upside than the headline average.

Technical Levels and Market Structure

The shares recently pressed toward the 52-week high near $31.50, a clear overhead resistance zone; a decisive break above it would open the next notable levels around $32–$33. On the downside, support appears in the $28–$29 area from recent consolidation, with the 50-day moving average near $27.50 and the 200-day moving average near $25.40 providing deeper cushions. The 52-week low sits near $16, underscoring how far the stock has already run and the distance between current prices and any meaningful long-term base. From what I see, these levels help frame where momentum could shift next.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a research horizon of roughly 12 months, though individual firms rarely publish a uniform horizon, and some targets in the set may reflect longer-range sum-of-the-parts thinking. Investors should watch third-quarter results and any updates to 2026 guidance, clinical and regulatory milestones for zanidatamab, integration progress from the Theravance deal, further analyst revisions, and broader biotech sentiment and interest-rate conditions. Short interest and insider activity are secondary signals worth tracking alongside fundamentals. I’m watching this closely as the next earnings release approaches.

Using AI Daily Buy/Sell Signals for Timing

In my research process, I often turn to Tickeron’s AI Daily Buy/Sell Signals to get an additional layer of data-driven insight on names like ZYME. The tool scans thousands of stocks and generates signals based on technical behavior and market conditions, which can complement the fundamental picture when deciding on entry or exit points.

Final Assessment

The $42 central target, derived from the mean of 14 analyst targets ranging from $32 to $58, implies roughly 36% upside from a recent price near $30.80. Support rests on sharply higher 2026 revenue guidance, the Theravance acquisition, a clean balance sheet, and a uniformly bullish—and recently rising—analyst consensus. The principal obstacles are a rich trailing valuation, ongoing losses, and genuine execution and clinical risk, reflected in the unusually wide spread between the lowest and highest targets. Investors should focus on third-quarter results, guidance updates, and pipeline milestones rather than treating the $42 figure as a forecast or a guarantee.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume